In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at </=4 microgram/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.
García-Garrote
F
F
Servicio de Microbiología, Hospital General Universitario "Gregorio Marañón," Madrid, Spain. fgarrote@efd.net
Cercenado
E
E
Alcalá
L
L
Bouza
E
E
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D006020:Glycopeptides; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin